Incyte Corp
INCA033989
essential thrombocythemia / myelofibrosis
Resolved
188days ago
Phase 1 readout · ~ Dec 31, 2025 estimated
What's at stake
Phase 1 trial results for INCA033989 in essential thrombocythemia / myelofibrosis are due ~ Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“In December, clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989 as a treatment for mutCALR-positive essential thrombocythemia (ET) and myelofibrosis (MF) were presented at the 2025 ASH Annu”